newsfilter
← Latest News
Business Wire·

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

ACH
  • Accendra Health will not implement its planned at-the-market equity issuance program due to current market conditions.
  • The cancelled program was intended to opportunistically reduce outstanding indebtedness and was never a source of operational liquidity.
  • The decision not to proceed with the issuance program will have no impact on the Company's results of operations or published guidance.
  • The Company maintains confidence in its liquidity position due to increasing cash collections & resolving payor collection issues.
  • Accendra Health was undrawn on its $300 million revolving credit facility at the end of Q2 & expects to use it only for occasional working capital fluctuations.
  • The Company remains committed to strengthening its balance sheet & reducing leverage.
  • A sale of one non-core asset closed in Q3, with a second sale expected to close before year-end.
  • These two asset sales represent a combined cash injection of approximately $45 million in Q3 & Q4.
  • The asset sales will have a de minimis impact on the Company's Adjusted EBITDA.
  • The Board of Directors is actively evaluating candidates for CEO following Mr. Pesicka's announced retirement by end of 2026.
  • The Board expects to announce a successor by mid-September 2026 to ensure a timely leadership transition.
  • Mr. Pesicka will continue serving as CEO until his successor is appointed & will serve in an advisory capacity post-transition.